CTOs on the Move

BC Biomedical Laboratories

www.bcbio.com

 
BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.bcbio.com
  • 7455 130 St
    Surrey, BC CAN V3W 1H8
  • Phone: 604.507.5000

Executives

Name Title Contact Details

Similar Companies

RootPath Genomics

RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.

Croda

Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

hhoaltd

hhoaltd is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Empirico

Empirico is a venture-backed, next-generation therapeutics company founded on utilizing huge biological data sets, human genetics and programmable biology to power novel target discovery and development.

Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry`s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma`s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson`s Imbruvica, Astellas` and Pfizer`s Xtandi, Biogen`s Tysabri, Johnson & Johnson`s Tremfya, Gilead`s Trodelvy, Merck`s Januvia, Novartis` Promacta, Vertex`s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.